Want to see AU:ALC full AI Analyst Report?
ALC Stock Chart & Stats
AU$0.09
>-AU$0.01(-3.37%)
At close: 4:00 PM EDT
AU$0.09
>-AU$0.01(-3.37%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.15
Previous CloseN/A
Volume2.06M
Average Volume (3M)796.98K
Market Cap
AU$122.26M
Enterprise ValueAU$127.81
Total Cash (Recent Filing)AU$14.20M
Total Debt (Recent Filing)AU$1.32M
Price to Earnings (P/E)31.0
Beta0.97
Next Earnings
Aug 19, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,343,558,700
10 Day Avg. Volume536,053
30 Day Avg. Volume796,979
Financial Highlights & Ratios
PEG Ratio-0.70
Price to Book (P/B)1.57
Price to Sales (P/S)3.38
P/FCF Ratio24.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.14Price Target Upside58.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$53.97M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthConsistent top-line growth near mid-teens suggests expanding product adoption across hospitals and health services. In a software-led model, steady revenue growth supports longer-term contract momentum, recurring license renewals and cross-sell opportunities that underpin durable cash flows and scaling.
Very High Gross MarginAn ~88% gross margin reflects the scalability of clinical software and low incremental cost to serve additional sites. High gross margins provide structural room to invest in sales, R&D and support, and make margin expansion achievable as recurring revenue scales and implementation-driven costs are spread over larger recurring base.
Very Low Financial LeverageExtremely low leverage gives the company durable financial flexibility to fund implementations, invest in product development, or withstand reimbursement/contract timing risk without needing external financing. Low debt reduces refinancing and interest rate vulnerability over the medium term.
Bears Say
Negative EBIT MarginNegative EBIT indicates operating expenses currently exceed operating profits, suggesting the company has yet to achieve consistent operating leverage. Sustained profitability depends on converting revenue growth into operating margins by optimizing SG&A and implementation cost structures.
Thin Net ProfitabilityA low net margin despite high gross margins signals pressure from overhead, sales or implementation costs and limits free cash available for reinvestment or returns. Modest profitability constrains ROE and makes the business more exposed to cost increases or slower contract wins.
Contract / Implementation DependencyHeavy reliance on winning and executing multi-year hospital contracts creates long sales cycles, lumpy revenue and execution risk. Implementation and services variation can depress margins and make growth cadence uneven, raising structural execution risk over the medium term.
Alcidion Group Limited News
ALC FAQ
What was Alcidion Group Limited’s price range in the past 12 months?
Alcidion Group Limited lowest share price was AU$0.08 and its highest was AU$0.14 in the past 12 months.
What is Alcidion Group Limited’s market cap?
Alcidion Group Limited’s market cap is AU$122.26M.
When is Alcidion Group Limited’s upcoming earnings report date?
Alcidion Group Limited’s upcoming earnings report date is Aug 19, 2026 which is in 6 days.
How were Alcidion Group Limited’s earnings last quarter?
Alcidion Group Limited released its earnings results on Feb 25, 2026. The company reported AU$0.001 earnings per share for the quarter, beating the consensus estimate of AU$0 by AU$0.001.
Is Alcidion Group Limited overvalued?
According to Wall Street analysts Alcidion Group Limited’s price is currently Undervalued.
Does Alcidion Group Limited pay dividends?
Alcidion Group Limited does not currently pay dividends.
What is Alcidion Group Limited’s EPS estimate?
Alcidion Group Limited’s EPS estimate is 0.
How many shares outstanding does Alcidion Group Limited have?
Alcidion Group Limited has 1,343,558,700 shares outstanding.
What happened to Alcidion Group Limited’s price movement after its last earnings report?
Alcidion Group Limited reported an EPS of AU$0.001 in its last earnings report, beating expectations of AU$0. Following the earnings report the stock price went down -4.545%.
Which hedge fund is a major shareholder of Alcidion Group Limited?
Currently, no hedge funds are holding shares in AU:ALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alcidion Group Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$0.14 (58.33% Upside)
AU$0.14 (58.33% Upside)
Blogger Sentiment
Bullish
AU:ALC Sentiment 100%
Sector Average 61%
Sector Average 61%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
66.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.82%
Trailing 12-Months
Company Description
Alcidion Group Limited
Alcidion Group Limited operates as a healthcare technology firm, specializing in the creation and licensing of software products across Australia, New Zealand, and the United Kingdom. Its flagship product, Miya Precision, is a consolidated platform built on the Fast Healthcare Interoperability Resources (FHIR) standard, aimed at enabling intelligent healthcare delivery. The company also supplies Smartpage, a mobile and web-based system designed to streamline hospital communications and task management for clinical and administrative personnel. Additional solutions include Patientrack, a tool for real-time patient monitoring and risk screening; Silverlink, which handles patient administration; and ExtraMed, software dedicated to optimizing clinical and patient flow. Furthermore, Alcidion provides a range of services encompassing product deployment, support and maintenance, systems integration, and data analysis. Founded in 2000 and headquartered in South Yarra, Australia, the company was formerly known as Alcidion Corporation Pty Ltd until its rebranding as Alcidion Group Limited in December 2015.
ALC Stock 12 Month Forecast
Average Price Target
AU$0.14
▲(58.33% Upside)
Technical Analysis
Oneview Healthcare Chess Depository Interests repr 1
―
Pro Medicus Limited
―
Mach7 Technologies
―
Beamtree Holdings Ltd
―
Artrya Limited
―